| pubmed-article:15517588 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0024202 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0678222 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0279781 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0008902 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C1533716 | lld:lifeskim |
| pubmed-article:15517588 | lifeskim:mentions | umls-concept:C1999230 | lld:lifeskim |
| pubmed-article:15517588 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:15517588 | pubmed:dateCreated | 2004-11-24 | lld:pubmed |
| pubmed-article:15517588 | pubmed:abstractText | Adjuvant chemotherapy for patients with lymph node-negative breast carcinoma is being recommended currently based on the St. Gallen classification. The prognostic importance of HER-2 status in patients with lymph node-negative breast carcinoma has been investigated extensively, with contradictory results. The authors investigated the clinical relevance of HER-2 overexpression when combined with the St. Gallen classification in lymph node-negative breast carcinoma. | lld:pubmed |
| pubmed-article:15517588 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15517588 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15517588 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15517588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15517588 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15517588 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15517588 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15517588 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:ImSeock-AhSA | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:KimTae-YouTY | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:ChoeKuk JinKJ | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:ParkIn AeIA | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:NohDong-Young... | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:KimNoe... | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:BangYung-JueY... | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:HeoDae SeogDS | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:HanWonshikW | lld:pubmed |
| pubmed-article:15517588 | pubmed:author | pubmed-author:SunJong-MuJM | lld:pubmed |
| pubmed-article:15517588 | pubmed:copyrightInfo | (c) 2004 American Cancer Society | lld:pubmed |
| pubmed-article:15517588 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15517588 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15517588 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:15517588 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15517588 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15517588 | pubmed:pagination | 2516-22 | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:meshHeading | pubmed-meshheading:15517588... | lld:pubmed |
| pubmed-article:15517588 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15517588 | pubmed:articleTitle | A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. | lld:pubmed |
| pubmed-article:15517588 | pubmed:affiliation | Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. | lld:pubmed |
| pubmed-article:15517588 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15517588 | lld:pubmed |
